Saturday 17 October 2026
Export CLVR’s income statement to Excel — free account
Clever Leaves Holdings Inc.
CLVR Healthcare Drug Manufacturers Specialty & Generic
Clever Leaves Holdings Inc.’s revenue for fiscal 2023 (year ended December 2023) was $17.4 million, up 6.14% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
0.01
0.00
0.00%
Follow CLVR
Clever Leaves Holdings Inc. (CLVR) P/E ratio
Clever Leaves Holdings Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 57.5× (March 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 57.5×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| CLVR Clever Leaves Holdings Inc. | n/m |
| ORGO Organogenesis compare | n/m |
| PROCF Sofgen Pharma S.A compare | 0.1× |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 144× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)